2026 International Spring Forum
April 15, 2026 | 12:00 PM EST
Bispecific T-Cell Engagers in Non-Hodgkin Lymphoma: Treatment Discussion Guide
Last Updated: April 24, 2025
Empowering the Entire Oncology Team
Delivering high-quality, patient-centered education requires every member of the medically integrated oncology team working in sync—each contributing their expertise to support, inform, and empower patients. That’s the mission behind NCODA’s newest resource: the Medically Integrated Oncology Treatment Discussion Guide for Bispecific T-Cell Engagers in Non-Hodgkin Lymphoma.
This structured discussion guide equips oncologists, advanced practice providers, pharmacists, pharmacy technicians, and nurses with practical insights to support treatment conversations throughout the patient journey. From therapy selection and step-up dosing to monitoring, toxicity management, and medication access, the guide helps ensure consistent messaging while honoring the unique role each team member plays in delivering coordinated, high-quality care.
Key Features of the Guide Include:
- Role-Specific Questions & Recommendations
Thoughtful prompts tailored to physicians/APPs, pharmacists, nurses, and pharmacy technicians to help guide meaningful patient discussions and streamline interdisciplinary collaboration. - Actionable Patient Education Pearls
Practical guidance on treatment expectations, adherence, monitoring, supportive medications, and recognizing serious adverse events such as cytokine release syndrome (CRS) and ICANS. - Patient-Centered, Team-Based Care
Every section is designed to promote consistent communication, proactive follow-up, and safer care delivery—supporting patients and caregivers during treatment initiation and beyond.
This guide doesn’t replace clinical judgment, it strengthens it. Use it to structure conversations, align workflows, and foster true teamwork to support safe and effective implementation of bispecific antibody therapy in NHL.
Download the Medically Integrated Oncology Treatment Discussion Guide for Bispecific T-Cell Engagers in Non-Hodgkin Lymphoma today to enhance your treatment discussions and interdisciplinary care.